Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis

NACompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

March 5, 2025

Study Completion Date

March 5, 2025

Conditions
Reversal of Neuromuscular Blockade
Interventions
DRUG

Sugammadex

"After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.~Dose will be according to participant actual body weight."

DRUG

Neostigmine

"After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.~Dose will be according to participant actual body weight."

Trial Locations (2)

100000

Beijing tongren Hospital, Capital Medical University, Beijing

210000

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

lead

Beijing Tongren Hospital

OTHER

NCT06436768 - Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis | Biotech Hunter | Biotech Hunter